Matthew Arnold

 
 

Recent Articles

Everyday Health launches virtual doc

January 15, 2010

Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.

McCann creates 'Office of the CEO'

January 15, 2010

McCann Healthcare Worldwide announced a new "Office of the CEO" under which four executives will share leadership responsibility.

NuvaRing DTC leads web traffic

January 15, 2010

NuvaRing and Latisse lead the pack in DTC-driven traffic to their brand.com sites, according to Manhattan Research.

FDA takes microsite back to 'Basics'

January 15, 2010

The FDA unveiled the first fruit of its transparency initiative with FDA Basics, a microsite aimed at demystifying the agency's workings for the public.

Lebhar-Friedman sheds four titles

January 15, 2010

B2B media firm Lebhar-Friedman sold the journals division of Dowden Health Media to Quadrant HealthCom in a move it said was designed to decrease reliance on advertising-based businesses.

Everyday Health's virtual doc dispenses compliance advice

January 14, 2010

Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.

DDMAC cites fishy Cymbalta fibromyalgia ads

January 14, 2010

The FDA issued an untitled letter upbraiding Lilly for Cymbalta consumer and professional ads.

FDA launches "Basics" transparency microsite

January 13, 2010

The FDA unveiled the first fruit of its transparency initiative with the launch of FDA Basics, a microsite aimed at demystifying the agency's workings for the public.

Sharp Rx price jumps way up, says GAO

January 12, 2010

A Government Accountability Office study found "extraordinary price increases" in 416 branded drug products (across 321 brands) between 2000 and 2008. That's about half of one percent of all branded drug products.

Pfizer $3m Stanford CME grant comes with few strings attached

January 11, 2010

In the debate over industry support of CME, it's often been argued that drug and device manufacturers would never support programming that they had no control over. Pfizer's $3 million, three-year grant to Stanford University School of Medicine suggests otherwise, though the grant will support education around areas of "mutual interest" and will be disbursed in milestone payments.